<DOC>
	<DOCNO>NCT00822783</DOCNO>
	<brief_summary>Elevated level immunoglobuline E blood say promote occurence atopic dermatitis ; fact , many patient atopic dermatitis high IgE level . This study try explore whether depletion IgE blood skin might result change immunological parameter might alter clinical course disease .</brief_summary>
	<brief_title>Study Determine Effect Anti-IgE Agent Inflammatory Cells Skin Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>age 12 60 year clinical diagnosis AD ( criterion Hanifin Rajka , 1980 ) serum IgE 30 1,300 IU/ml least one significantly positive RAST positive skin prick test specificity RAST Investigator ` Global Assessment Score 2 randomization stable AD , define active AD ( IGA 2 ) &gt; 9 month per year sign informed consent . pregnant nursing female woman childbearing potential use reliable contraceptive method treatment omalizumab within last 12 month study treatment know hypersensitivity ingredient omalizumab omalizumab relate drug elevate serum IgE level reason atopy ongoing immunotherapy use longacting antihistamine astemizol within 3 month prior visit1 use mediumacting antihistamine ( e.g . loratadine , cetirizine ) within 5 day prior visit 1 use shortacting antihistamine ( e.g . diphenhydramin , terfenadine ) within 3 day prior visit 1 use zafirlukast leukotriene receptor inhibitor zileuton 5lipoxygenase enzyme inhibitor within 3 day prior visit 1 use phototherapy systemic therapy know suspected effect AD within 1 month prior first application study medication treatment topical therapy ( hydrocortisone 1 % ) know suspected effect AD within 14 day prior first application study medication use systemic steroid ( oral , intravenous , include intraarticular rectal ) within one month prior first application study medication . ( Patients stable maintenance dose inhaled steroid allow participate ) use systemic antibiotic within 2 week prior first application study medication use tranquilizer , hypnotic agent tricyclic antidepressant within 2 week prior start study immunocompromised patient patient history malignant disease concurrent skin disease active bacterial , viral fungal infection require treatment prohibited medication history recurrent herpes simplex infection active lesion baseline tinea corporis / tinea cruris clinically significant laboratory abnormality history noncompliance medical regimen patient consider potentially unreliable evidence drug alcohol abuse factor limit ability fully cooperate condition prior/continuing treatment , opinion investigator , render patient ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Serum IgE level</keyword>
	<keyword>inflammatory cell skin</keyword>
	<keyword>inflammatory cell blood</keyword>
	<keyword>IgE</keyword>
	<keyword>IgE depletion</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>atopic eczema</keyword>
	<keyword>Omalizumab</keyword>
</DOC>